Steve Kanner

Chief Scientific Officer • Caribou Biosciences

Steve is the Chief Scientific Officer of Caribou Biosciences responsible for the company’s therapeutic discovery, research, and development activities. Before joining Caribou in 2017, Steve was Vice President, Head of Biology, at Arrowhead Pharmaceuticals, leading a department in discovery of RNAi therapeutics for oncology, genetic diseases, and other indications. Prior to Arrowhead Pharmaceuticals, he served in various positions of increasing responsibility in both oncology and inflammation drug discovery at Bristol-Myers Squibb, Agensys/Astellas, and Astex Pharmaceuticals. Steve has authored over 85 publications in both peer-reviewed journals and books, and he is an inventor on numerous U.S. and foreign patents and patent applications. Steve received his undergraduate degree in Genetics from the University of California, Berkeley and his Ph.D. in Immunology and Microbiology from the University of Miami’s Miller School of Medicine. His post-doctoral fellowship was funded by the National Institutes of Health and was conducted at the University of Virginia.

Also Speaking

Lili Belcastro

Senior Principal Scientist, Cell and Gene Therapy Raw Materials • Bristol Myers Squibb

Olivia Drew

Portfolio Manager • UBS UK Life Sciences

Jacqueline Barry

Chief Clinical Officer • Cell and Gene Therapy Catapult

Also Speaking


Post-Event Report

Download the post-event report for Advanced Therapies Week 2024.

Investor List

Take a look at some of the investors who attended Advanced Therapies Week 2023.